Based in Boston, UrSure is developing and commercializing products that measure adherence to HIV medications including pre-exposure prophylaxis or PrEP, the daily medication to prevent HIV. This includes laboratory-based tests that can measure levels of the medication in a patient’s urine or blood, as well as several additional point of care products in development.
UrSure received $200,000 through MLSC Milestone Achievement Program (MAP). MAP was designed to address the needs of early-stage life sciences companies by providing grant funding to execute critical, value-creating technical milestones. The MLSC’s investment equated to 10% at the time of funding.